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Abstract
Epithelial ovarian cancer is the fifth leading cause of cancer mortality among women in the United
States. For this disease, differences in age-adjusted incidence and survival rates between African
American and Caucasian women are substantial. The objective of this study was to examine
mtDNA sequence variants in 118 frozen tissues of three subtypes of epithelial ovarian cancer
(serous, n = 48 endometrioid, n = 47 and mucinous, n = 23) and matched paracancerous normal
tissues (n = 18) in relation to racial/ethnic and age differences. Restriction fragment length
polymorphism (RFLP) and polymerase chain reaction (PCR)-based sequencing were used to
evaluate two regions of mtDNA spanning 5317 to 7608 and 8282 to 10110 bp and including ND
subunits 2, 3, MT-COI, II, and III, ATPase 8, a part of ATPase 6, and tRNA genes in frozen ovarian
tissues obtained from the southern regional Cooperative Human Tissue Network (CHTN) and
University of Alabama-Birmingham (UAB) Ovarian Spore Center. Thirty-nine mtDNA variants
were detected of which 28 were previously unreported. One somatic variant of C9500T was
observed. A variant, C7028T in the MT-CO1 gene, had an ascending frequency from borderline (8%)
to stages III/IV (75%) among the three ovarian cancer subtypes and stages. It was found in 86% (42/
49) of African-American and 43% (37/87) of the Caucasian women. A variant, T8548G in the ATPase
6 gene was detected at a frequency of 72% (18/25) in ovarian serous subtype tissues in stages III/
IV. Of the African American patients under age 40, 95% (20/21) harbored the T8548G variant; this
was in contrast to only 22% (8/35) of Caucasian patients in same age group. Variants C7256T and
G7520A had a frequency of 54% (6/11) in endometrioid stage III; no corresponding variants were
observed in mucinous subtype stage III. Furthermore, variants C7256T and G7520A were absent
in serous ovarian cancer subtype. Interestingly, the C7520T variant in tRNA gene was present in
74% (36/49) of African American and 26% (23/87) of Caucasian patients. Taken together, our
results suggest that, with respect to ethnic and age difference, these mtDNA variants may be
involved in epithelial ovarian carcinogenesis.
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Findings
Although early diagnosis provides the best chance for cure
in patients with epithelial ovarian cancer, the lack of
appropriate diagnostic strategies continues to confound
clinical oncologists. Hence, there is a pressing need for a
specific, less-invasive procedure to allow accurate subtyp-
ing and staging evaluation of epithelial ovarian cancers
for early detection and treatment strategies. Most ovarian
cancers occur in older women, and mtDNA mutations are
thought to have a causal role in many age-related pathol-
ogy because of mitochondria involvement in cell apopto-
sis and reactive oxygen species (ROS) activities [1-5].
Mitochondrial gene products are essential for normal cell
functions and all mitochondria within a cell share identi-
cal DNA sequence. MtDNA sequence within the same cell
may be preferentially modified by carcinogens and
mtDNA is repaired less efficiently compared with that of
nuclear DNA [6], as a result, it has been implicated in car-
cinogenesis [2-5,7].
Sequence variants in certain regions of mtDNA have been
associated with ovarian cancer [7,8]. Between African-
American and Caucasian women with this disease, there
are differences in age-adjusted incidence and survival rates
[9]. Nevertheless, definitive mtDNA sequence variants in
epithelial ovarian carcinogenesis in relation to racial/eth-
nic and age differences have yet to be established. Given
the connection between mitochondria, ROS, and neopla-
sia, mtDNA from three subtypes of ovarian cancer stages
(including the borderline and cystadenoma) and matched
paracancerous normal tissues were screened for mtDNA
sequence variants that might be used as potential prog-
nostic markers for ovarian carcinogenesis in relation to
racial/ethnic and age differences. We speculated that there
is an association between one or more mtDNA sequence
variants and ovarian cancer incidence with respect to dif-
ferences in ethnicity and age. In this study, we analyzed
sequence variants in two regions of mtDNA obtained
from 118 epithelial ovarian cancer and 18 matched para-
cancerous normal tissues spanning 5317 to 7608 and
8282 to 10110 bp, including ND subunits 2 and 3; MT-
COI, II, and III; ATPase 8; part of ATPase 6; and tRNA
genes.
All studies were implemented under protocols approved
by Institutional Review Boards of Morehouse School of
Medicine and UAB.
One hundred and eighteen frozen epithelial ovarian can-
cer tissues from three histologic subtypes [(serous n = 48;
endometrioid, n = 47; mucinous n = 23), including stages
I-IV, benign cystadenomas, borderline tumors] and 18
matched paracancerous normal tissues that paired with
some of the tumors were obtained from CHTN and UAB-
Ovarian Spore Center. Ovarian cancer subtype and clin-
icopathologic stage tissues were histologically determined
based on the criteria outlined by AJCC. Of the tissues, 49
of the tissues were African American and 87 tissues were
Caucasian women. The mean age of the patients was 51.3
± 5.7 years. MtDNA was isolated from the frozen tissues
using centrifugation according to the manufacturer's pro-
tocols (BioVision, Research Products). Total mtDNA was
quantified and diluted to 50 ng/μl for PCR reaction.
MtDNA variants were detected by use of RFLP and PCR-
based sequence as previously described [7]. Sequences of
both sense and anti-sense strands were derived with an
ABI 3100 Genetic Analyzer. Sequences were aligned and
compared to mitochondrial DNA sequences [GenBank:
J01415] in relation to ovarian cancer subtypes, stages, eth-
nicity and age of the patients. The MITODAT database was
used to determine sequence variants.
Sequence analyses revealed the presence of thirty-nine
variants, of which 28 were previously unreported [see
Additional file 1]. These previously reported variants were
observed: C7028T, C7256T, G7520A, T8548G, T8588C,
A8860G, C9488G, C9500T, T9540C, C9857T, T9951C,
10045delA. Some of the unreported variants were
G7520A, T8548G, C9488G, C9500T, C9857 and T9951C;
frequencies ranged from 41–93 percent. Additionally, a
somatic variant of C9500T was observed. Variants
C7028T 82/136 (60%) and A8860G 125/136 (93%) were
evenly distributed in the three ovarian cancer subtypes
and stages. The variant C7028T in the MT-CO1  gene,
which had an ascending frequency from borderline (8%)
to stages III/IV (75%) among the three ovarian cancer sub-
types and stages, was found in 86% (42/49) of African-
American and 43% (37/87) of Caucasian patients (figures
1A and 1B). Although germ-line mutations in the MT-COI
gene of mtDNA are thought to influence the incidence of
prostate cancer in African American men [4], it is unclear
whether this particular variant of C7028T is involved in
epithelial ovarian carcinogenesis as one of the genetic risk
factors for racial/ethnic differences in ovarian disease. The
present evidence, in spite of the limited sample size, is
consistent with such involvement. A variant, G8860A, was
observed in the ATPase 6 gene at a frequency of 93%. Even
though this ATPase 6 gene influenced the ROS produc-
tions [2,4-6], it is not known if this mutation contributes
to a common mechanism related to the onset and pro-
gression of epithelial ovarian cancer subtypes and stages.
The most striking aspect of our results regarding age
groups is that the T8548G variant in the ATPase 6 gene was
present at a frequency of 72% (18/25) among the subtype
of serous ovarian cancer stages III/IV. Of African-American
patients under the age 40 with serous ovarian cancer, 95%
(20/21) harbored the T8548G variant compared to 22%
(8/35) of Caucasian patients of same age group (figures
1C and 1D). Notably, variant T8548G was not detected inDiagnostic Pathology 2008, 3:32 http://www.diagnosticpathology.org/content/3/1/32
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Graph illustrating the differences in ethnicity, age and the number of mtDNA sequence variants obtained from three subtypes  (serous, endometrioid and micinous) of epithelial ovarian cancer stages using following primers; F 5'-CCACCATCACCCTCCTT-3',  and R 5'-CCTACTTGCGCTGCATGTGCC-3' and F 5'-CCCCTCTAGAGCCCACTGTAAAGC-3', R 5'-GTAGTAAGGCTAGGAGGGTG-5 Figure 1
Graph illustrating the differences in ethnicity, age and the number of mtDNA sequence variants obtained from three subtypes 
(serous, endometrioid and micinous) of epithelial ovarian cancer stages using following primers; F 5'-CCACCATCACCCTCCTT-3', 
and R 5'-CCTACTTGCGCTGCATGTGCC-3' and F 5'-CCCCTCTAGAGCCCACTGTAAAGC-3', R 5'-GTAGTAAGGCTAGGAGGGTG-5; (A), 
Cumulative frequency of the C7028T variant observed in three subtypes of epithelial ovarian cancer stages; B, ethnic related 
frequency of C7028T variant observed between African American and Caucasian women with ovarian cancer; C, frequency of 
T8548G variant among the three subtypes and stages of epithelial ovarian cancer; D, frequency of T8548G variant observed in 
relation to age between African American and Caucasian women with ovarian cancer; E, electropherogram indicating nucle-
otide G observed in some of the three epithelial ovarian cancer tissues; F, electropherogram indicating nucleotide T in all the 
colorectal cancer tissues tested as positive controls; G, frequency of the C9500T variant in relation to stages of the three epi-
thelial ovarian cancer ; H, frequency of the C9500T variant in relation to age between African American and Caucasian women 
with ovarian cancer.
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the 14 samples of colorectal cancer tested as "positive con-
trols" (figures 1E and 1F).
Moreover, the somatic variant C9500T occurred with a
frequency of 52% (12/25) in serous ovarian cancer stages
III/IV. Of African American patients under age 40, 47%
(10/21) harbored the variant, compared to 1% (2/35) of
Caucasian patients. Among Caucasian patients over age
60, however, the frequency of the C9500T variant was
60% (21/35), compared with 23% (5/21) for African
American patients (figures 1G and 1H). Although the
function of these mtDNA variants (perhaps in combina-
tion with other mtDNA mutations) in relation to the age-
specific racial/ethnic difference is unclear, ovarian cancer
generally occurs after menopause and is related to old age
[10]. Nevertheless, these findings support the concept that
there is a pronounced ethnic difference for younger and
older women with more advanced ovarian cancer [9]. Fur-
thermore, African American patients under age 40 with
this disease have more rapid progression and poorer sur-
vival rates compared with Caucasian patients [11]. Ran-
dom genetic drift may explain the accumulation of
mtDNA mutations with age [12]. Age is an important risk
factor for ovarian cancer: approximately 70% of cases
occur in women over the age of 55 [13]. In the present
study, the patients' age at the time of surgery ranged from
28 to 71 years (median age 51.3). These variants may
function in combination with other risk factors [9] in the
advancement of serous ovarian cancer in African Ameri-
can patients relative to Caucasian patients.
Comparison of sequence variants among the three ovar-
ian cancer subtypes revealed a combined variant, C7256T
and G7520A, with a frequency of 54% (6/11) in endome-
trioid stage III, but there was no correspondence in inci-
dences in mucinous subtype stage III. In addition, variants
C7256T and G7520A were absent in serous ovarian cancer
subtype. The C7520T variant in tRNA gene occurred in
74% (36/49) of African American and 26% (23/87) of
Caucasian among patients. Furthermore, a sequence vari-
ant T9540C in the MT-COIII gene was observed at a high
frequency in 88% (42/49) of African American patients
compared with Caucasian patients at 10% (9/87); this
variant was not found in the mucinous subtype samples.
We had expected that, in many cases, the mtDNA
sequence data in the three ovarian cancer subtypes would
be similar. Because the three epithelial tumors (serous,
mucinous, and endometrioid) are thought to share a com-
mon cellular ancestry with other structures of the repro-
ductive tract and since metaplasia of the cyst lining give
rise to growths of serous, mucinous, or endometrioid cells
[14]. Moreover, mtDNA mutations in the tRNA gene are
highly conserved [6] and accumulate with age, particu-
larly during the increased mitotic and post-mitotic activi-
ties accompanying ovulation and repair [15].
Nevertheless, it possible that etiologic features of the com-
mon epithelial ovarian cancer subtypes differ because of
development from cells that already histological differen-
tiated [16].
In this study, we have observed that, in regard to mtDNA
from African American women and Caucasian women
with epithelial ovarian cancer, there is an appreciable dif-
ference in the frequency of sequence variants in relation to
age. As a result of the fact that mtDNA sequence variants
may accumulate as ovarian cancer progresses through dif-
ference stages, mtDNA and mitochondria may be
involved in the process of epithelial ovarian carcinogene-
sis. Based on this study and others, we suggest that the epi-
thelial ovarian cancer subtypes (serous, mucinous and
endometrioid) may be etiologically unrelated and thus
should be considered as difference entities. However,
larger, population-based studies are required to quantify
the functional role of mtDNA sequence variants in histo-
logical subtypes and stages of ovarian cancer. Since we
sequenced only a 4.1 kb fragment of the 16.5 kb mito-
chondrial genome, the number of mtDNA sequence vari-
ants that could correlate with ovarian tumor subtypes and
stages may exceed the number we observed.
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